For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Income tax benefit | 0 | |||
| General and administrative | 15,447,000 | |||
| Research and development | 8,604,000 | |||
| In-process research and development impairment | 0 | |||
| Total operating costs and expenses | 24,051,000 | |||
| Loss from operations | -24,051,000 | |||
| Foreign currency exchange gain (loss) | 25,000 | |||
| Interest income | 287,000 | |||
| Total other income | 312,000 | |||
| Net loss before income taxes | -23,739,000 | |||
| Profit Loss | -23,739,000 | |||
| Deemed Dividend From Warrant Inducement | 1,500,000 | |||
| Net loss attributable to common stockholders | -25,249,000 | |||
| Basic EPS | -2.08 | |||
| Diluted EPS | -2.08 | |||
| Basic Average Shares | 12,140,697 | |||
| Diluted Average Shares | 12,140,697 | |||
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)